Frequency and clinical outcome of potentially harmful drug metabolic interactions in patients hospitalized on internal and pulmonary medicine wards: Focus on warfarin and cisapride

Therapeutic Drug Monitoring

Volumn 22, Issue 5, 2000, Pages 503-509

  Laine, Kari ^a   Forsström, Jari ^b   Grönroos, Paula ^a   Irjala, Kerttu ^a   Kailajärvi, Marita ^a   Scheinin, Mika ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b Medical Informatics Research Centre in Turku (MIRCIT)   (Finland)

Author keywords

Cisapride; CYP; Drug metabolism; Interaction; Warfarin

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; CARBAMAZEPINE; CISAPRIDE; CLARITHROMYCIN; CYTOCHROME P450; DEXTROPROPOXYPHENE; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; FLUOXETINE; GASTROINTESTINAL AGENT; METRONIDAZOLE; MICONAZOLE; PROKINETIC AGENT; RIFAMPICIN; SIMVASTATIN; WARFARIN;

ANTIBIOTIC THERAPY; ANTICOAGULANT THERAPY; ARTICLE; DRUG EFFICACY; DRUG METABOLISM; ELECTROCARDIOGRAM; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QT INTERVAL; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CISAPRIDE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FEMALE; FINLAND; GASTROINTESTINAL AGENTS; HOSPITAL RECORDS; HOSPITAL UNITS; HOSPITALIZATION; HUMANS; MALE; MEDICATION SYSTEMS, HOSPITAL; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); WARFARIN;

EID: 0033797962     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200010000-00001     Document Type: Article

References (40)

1. Drug interactions with the nonsedating antihistamines
2. Terfenadine-associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenance organization
3. Torsades de pointes after terfenadine-itraconazole interaction
4. The short life and rapid death of a novel antihypertensive and antianginal agent
5. From the Food and Drug Administration
6. What lessons can be learnt from withdrawal of mibefradil from the market?
7. Guidelines on oral anticoagulation
8. Detecting drug interactions: A review of the literature
9. Drug interactions in a clinic using COSTAR
10. Prescription of contraindicated and interacting drugs in elderly patients admitted to hospital
11. Drug interactions in primary health care. A retrospective database study and its implications for the design of a computerized decision support system
12. The stereoselective interaction of warfarin and metronidazole in man
13. A significant interaction between metronidazole and warfarin
14. Bleeding associated with concurrent warfarin and metronidazole therapy
15. Hemorrhagic complications of anticoagulant treatment
16. Interactions of warfarin with drugs and food
17. Disorders of blood coagulation
18. Anticoagulant, thrombolytic, and antiplatelet drugs
19. Anonymous Cisapride new contraindications
20. Anonymous Cisapride risk of arrhythmias
21. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers
22. Torsade de pointes induced by cisapride/clarithromycin interaction
23. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin
24. The effects of erythromycin on the electrocardiogram
25. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents
26. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction
27. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
28. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole
29. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole
30. Cisapride. Drug interactions of clinical significance
31. Interaction between warfarin and miconazole oral gel
32. Potentiation of warfarin action by miconazole oral gel
33. Interaction between miconazole oral gel (Daktarin) and warfarin
34. Potentiation of warfarin anticoagulant activity by miconazole oral gel
35. Derangement of warfarin anticoagulation by miconazole oral gel